Aussie health tech taps ex-AWS executive to lead AI strategy

Australian-founded health technology company i-screen has named senior executive Brad Ryan as its new Chief AI Officer, ramping up its push to turn data and artificial intelligence (AI) into real-world preventive health impact.

Ryan brings more than three decades of senior technology leadership experience, most recently heading the Data and AI partner business for Amazon Web Services across Asia Pacific and Japan. Before that, he spent 25 years at Accenture, rising to Managing Director and leading AI programs across ANZ and the broader Asia Pacific region.

From its roots in consumer pathology and screening, i-screen is rapidly evolving into a tech-powered engine for preventive health, early detection, and longevity insights. Founded over a decade ago by entrepreneur Amelia Thornycroft, the company has scaled across multiple international markets, delivering nearly one million diagnostic tests to more than 130,000 people across Australia, New Zealand, Singapore, and the United Kingdom.

In his newly created role, Ryan will spearhead i-screen’s AI, data, and technology strategy, embedding AI across the company’s screening programs, analytics capabilities, and population health initiatives.

“When we started i-screen, the goal was simple – to democratise health screening to support better health decisions,” Thornycroft said. “Over time, we built trusted laboratory partnerships, refined our screening programs and proved we could deliver at scale across multiple countries.”

“What’s changed is the opportunity. We now have the data, the reach and the clinical credibility to apply AI in a way that genuinely improves health outcomes. Brad’s experience operating at scale, in complex and regulated environments, makes him the right person to help guide that transition,” she added.

There is a global surge of interest in AI-enabled healthcare, fuelled by rising healthcare costs, ageing populations, and advances in cloud computing and machine learning. Major tech players including Microsoft and Alphabet are accelerating investment in healthcare-focused AI infrastructure, while startups race to turn innovation into tangible impact. OpenAI’s recent $100 million acquisition of Torch Health in January 2026 highlights the momentum behind personalised healthcare solutions.

i-screen Group CEO Scott Montgomery said “We’ve demonstrated that we can execute – across geographies, across large populations and in partnership with leading clinical providers. The question now is how we responsibly unlock more value from that footprint.

“AI allows us to move beyond static screening toward more predictive and personalised insights. Brad brings the rare combination of strategic perspective and hands-on delivery experience to help us do that properly.”

During his tenure at AWS, Ryan helped enterprises and technology partners accelerate adoption of AI, analytics, and machine learning across Asia Pacific. At Accenture, he advised organisations in healthcare, life sciences, consumer goods, natural resources, and the public sector on large-scale digital transformation, often in highly regulated environments.

“A lot of organisations talk about AI in health, but very few have real-world scale, trusted clinical frameworks and years of execution behind them,” Ryan said. “i-screen does. The opportunity here is to use data and AI not as an abstract capability, but as a practical tool for improving people’s lives – helping people understand risk earlier, supporting better decisions and ultimately improving long-term health outcomes.”

Ryan will also join the i-screen Board as a Director, bringing additional technology and governance depth as the company expands its international footprint.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.